We have observed
8 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after May 11, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INTENDED TO PREVENT MISUSE
PHARMACEUTICAL COMPOSITION COMPRISING FEXOFENADINE
PHARMACEUTICAL COMPOSITION COMPRISING DROTAVERINE
PHARMACEUTICAL COMPOSITION COMPRISING KETOPROFEN
ALCOHOL-FREE PHARMACEUTICAL COMPOSITION COMPRISING THYME AND PRIMULA ROOT LIQUID EXTRACTS
MARKED SOLID PHARMACEUTICAL FORM, AND METHOD FOR THE PRODUCTION THEREOF BY MEANS OF LASER MARKING
ZOLPIDEM-BASED ORODISPERSIBLE PHARMACEUTICAL TABLET
NOVEL SELECTION MARKER FOR CELL TRANSFECTION AND PROTEIN PRODUCTION